Quantcast
Home > Quotes > DCPH

Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) Quote & Summary Data

DCPH 
$21.68
*  
0.72
3.44%
Get DCPH Alerts
*Delayed - data as of Nov. 13, 2018 15:24 ET  -  Find a broker to begin trading DCPH now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    DCPH Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 21.63 / $ 21.73
1 Year Target
50
Today's High / Low
$ 23.405 / $ 20.83
Share Volume
283,077
50 Day Avg. Daily Volume
298,307
Previous Close
$ 20.96
52 Week High / Low
$ 45.61 / $ 15.15
Market Cap
816,494,838
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.58
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.7

Intraday Chart

Shares Traded

Share Volume:
283,077
50 Day Avg. Daily Volume:
298,307

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.58

Trading Range

The current last sale of $21.68 is 43.10% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 23.405 $ 45.61
 Low: $ 20.83 $ 15.15

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company developing new drugs to improve the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of many cancer therapies. Our targeted, small molecule drug candidates, designed using our proprietary kinase switch control inhibitor platform, inhibit the activation of kinases, an important family of enzymes, that when mutated or over expressed, are known to be directly involved in the growth and spread of many cancers. We have built a diverse pipeline of wholly owned, orally administered drug candidates that includes three clinical-stage and two research-stage programs. We are studying our lead drug candidate DCC-2618 in an ongoing pivotal Phase 3 trial in fourth-line plus treatment of gastrointestinal stromal tumors, or GIST, where there are currently no approved therapies, and in an ongoing Phase 1 trial in patients with advanced malignancies.  ... More ...  


Risk Grade

Where does DCPH fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 21.03
Open Date:
Nov. 13, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x